Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: ImmuCell operates in a single segment focused on the development, acquisition, manufacture, and sale of products to improve the health and productivity of cows for the dairy and beef industry. Key products include First Defense® and Wipe Out® Dairy Wipes. The company is heavily dependent on the successful development of new products, specifically Mast Out®, an intramammary infusion product utilizing Nisin.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 |
|---|---|---|
| Total Revenues | $845,563 | $2,752,581 |
| Net Income (Loss) | $(5,074) | $109,062 |
| Net Income Per Share (Diluted) | $(0.00) | $0.04 |
| Operating Cash Flow | N/A | $216,053 |
| Cash & Short-Term Investments | $4,241,096 (Total Liquidity) | $4,241,096 (Total Liquidity) |
| Working Capital | $5,118,662 | $5,118,662 |
| Long-Term Debt | $0 | $0 |
| Deferred Revenue (Long-Term) | $400,000 | $400,000 |
Note: Gross margin for the nine months ended September 30, 2004, was 59% of product sales.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9% ($220,000) for the nine months ended September 30, 2004, compared to the same period in 2003. Product sales increased 14% ($317,000).
- Profitability: The company reported a net income of $109,062 for the nine months ended September 30, 2004, compared to $539,241 in the prior year. The prior year's income was significantly inflated by a one-time $1,100,000 gain from the sale of a 50% interest in a non-core joint venture (AgriCell Company, LLC).
- Operating Expenses: Research and development (R&D) expenses decreased 16% ($138,000) to $735,366 for the nine-month period. Product selling expenses decreased 19% ($74,000) to $314,101, primarily due to the elimination of a marketing position in late 2003.
- Liquidity: Net cash provided by operating activities dropped to $216,053 from $1,337,556 in the prior year, largely due to the absence of the one-time joint venture sale proceeds in 2004. However, total liquid assets (cash and short-term investments) remained stable at approximately $4.24 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Mast Out® Development: This product is the primary focus of R&D investment. A pivotal efficacy trial is planned for the first half of 2005, with an objective to file for FDA approval in the first half of 2006 and begin commercial sales in 2007.
- Manufacturing: The company completed facility modifications in July 2004 to produce Nisin in-house, eliminating reliance on a subcontractor. This is expected to improve quality control and reduce inventory costs.
- Capital Resources: Management believes current capital resources are sufficient to meet working capital requirements and finance operations for at least the next twelve months.
Risks and Contingencies
- Regulatory Risk: Future growth depends on FDA approval for Mast Out®. Additionally, the USDA license for First Defense® relies on the stability of a "Reference Standard"; if requalification is denied, clinical studies may be required.
- Market Risk: The company is heavily dependent on the dairy industry, which faces economic pressures. Sales of Wipe Out® Dairy Wipes decreased 12% due to competition from less expensive products.
- Grant Repayment: The company holds $400,000 in deferred revenue from a Maine Technology Institute grant. If Mast Out® is commercialized, the company must either repay the grant in a lump sum or pay a 2% royalty on sales (totaling 2x the grant amount).
- Supply Chain: Production is concentrated at a single facility in Portland, Maine. Disruptions here would negatively impact inventory production.
Investor Verification Checklist
- One-Time Gains: Verify that the 2003 net income comparison is adjusted for the $1.1 million non-recurring gain from the joint venture sale to accurately assess operational performance.
- R&D Burn Rate: Monitor the $705,000 net R&D expense (after grant income) for the nine-month period and its impact on cash reserves relative to the timeline for the Mast Out® pivotal trial.
- Grant Obligations: Review the terms of the $400,000 and potential $500,000 Maine Technology Institute grants regarding repayment triggers upon commercialization.
- Customer Concentration: Note that Walco International, Inc. accounted for 18% of product sales and 17% of accounts receivable in the nine-month period.
- Regulatory Milestones: Track the initiation of the pivotal efficacy trial for Mast Out® scheduled for the first half of 2005.